- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Anticoagulant-induced Bleeding, Coronary Syndrome
- Interventions
- Unfractionated heparin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 2,161
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Coronary Heart Disease
- Interventions
- CLIMB intervention
- Behavioral
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 30 Years to 79 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Coronary Artery Disease
- Interventions
- Omacor, omega-3 fatty acids in CAD patients
- Drug
- Lead sponsor
- HeartDrug Research LLC
- Other
- Eligibility
- 50 Years to 60 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Towson, Maryland
- Conditions
- Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 285,327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
- Interventions
- (MC-1) Pyridoxal 5'-phosphate
- Drug
- Lead sponsor
- Medicure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Coronary Artery Disease
- Interventions
- Cardiac Catheterization
- Procedure
- Lead sponsor
- Minneapolis Heart Institute Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Coronary Artery Disease
- Interventions
- Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Bakersfield, California • La Jolla, California + 67 more
- Conditions
- Radial Artery Spasm, Angina, Coronary Artery Disease
- Interventions
- Topical Nitroglycerine, Topical Lidocaine
- Drug
- Lead sponsor
- Aultman Health Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Canton, Ohio
- Conditions
- Increased Drug Resistance
- Interventions
- Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo
- Drug · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Coronary Artery Disease, Endothelial Dysfunction
- Interventions
- darusentan 100 mg
- Drug
- Lead sponsor
- K.Lance Gould
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes, Hypercholesterolaemia, Hypertension, Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Heart Failure, CAD - Coronary Artery Disease, Stroke Risk, Cardiac Arrythmias, Genetics Hypertension, Genetics, Pharmacogenomics, Pharmacogenomic Testing for Medication Management, Cancer Genetics
- Interventions
- Color Genomics Genetic Testing Panels
- Genetic
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Tachycardia, Diabetes Mellitus, Cardiovascular Disease
- Interventions
- Subcutaneous Implantable Cardioverter Defibrillator
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 31 more
- Conditions
- Atherosclerosis, Diabetes, Coronary Artery Disease
- Interventions
- Nicotinamide riboside (NR), Placebo
- Dietary Supplement · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atherosclerosis, Coronary Disease
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-infectious Uveitis
- Interventions
- AIN457, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
- Conditions
- Myocardial Infarction
- Interventions
- placebo, PRT060128 Potassium
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 13
- States / cities
- Tallahassee, Florida • Des Moines, Iowa • Lexington, Kentucky + 10 more
- Conditions
- Cardiogenic Shock, Peripartum Cardiomyopathy, Complication, Pregnancy
- Interventions
- Extracorporeal Membrane Oxygenation
- Device
- Lead sponsor
- Sarah Thordsen
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson (Lexiscan) [muti-detector computed tomography]
- Device
- Lead sponsor
- Tennessee Heart and Vascular Institute, P.C.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Hendersonville, Tennessee
- Conditions
- Cardiovascular Diseases, Coronary Disease, Heart Diseases, Depression
- Interventions
- Psychoeducation; Treatment recommendations, Pharmacotherapy, Usual Care
- Behavioral · Drug · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acute Coronary Syndrome
- Interventions
- A-002, varespladib methyl, Placebo
- Drug
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 5,189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
- Conditions
- Coronary Heart Disease
- Interventions
- PAL2, CINEMA
- Behavioral · Other
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Type 2 Diabetes Mellitus, Coronary Artery Disease
- Interventions
- Aspirin
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Atherosclerosis, Coronary Artery Disease
- Interventions
- Percutaneous coronary intervention (Promus PREMIER)
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 48 more
- Conditions
- End Stage Kidney Disease
- Interventions
- CSL300, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 166
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more